lansoprazole + omeprazole

**Lansoprazole + omeprazole** is a **combination** of two proton pump inhibitors (PPIs). Both agents selectively inhibit the hydrogen/potassium ATPase enzyme system (the proton pump) of the gastric parietal cell, thereby suppressing gastric acid secretion. Lansoprazole and omeprazole are structurally similar substituted benzimidazoles and share the primary mechanism of irreversibly binding to and inhibiting the proton pump. These drugs are primarily indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, peptic ulcer disease, and Zollinger-Ellison syndrome. Both are available in oral formulations, both prescription and over-the-counter, and are widely used as monotherapies; a direct product combining both agents is not standard clinical practice and is not available as a marketed fixed-dose combination[3][5][4][8].

Other names

lansoprazole plus omeprazole